| Element | Wert |
|---|---|
| DrugBank ID | DB01030 |
| Evidenzniveau | L5 (Computergestützte Vorhersage) |
| Anzahl vorhergesagter Indikationen | 25 |
Die folgenden sind potenzielle neue Indikationen, die vom TxGNN-Modell vorhergesagt wurden. Höhere Punktzahlen deuten auf eine höhere vorhergesagte Relevanz hin.
| # | Indikation | Quelle |
|---|---|---|
| 1 | yolk sac tumor | TxGNN Knowledge Graph |
| 2 | hereditary breast ovarian cancer syndrome | TxGNN Knowledge Graph |
| 3 | ovarian adenocarcinoma | TxGNN Knowledge Graph |
| 4 | familial ovarian cancer | TxGNN Knowledge Graph |
| 5 | malignant germ cell tumor of ovary | TxGNN Knowledge Graph |
| 6 | ovarian clear cell adenocarcinoma | TxGNN Knowledge Graph |
| 7 | malignant non-dysgerminomatous germ cell tumor of ovary | TxGNN Knowledge Graph |
| 8 | hereditary site-specific ovarian cancer syndrome | TxGNN Knowledge Graph |
| 9 | borderline epithelial tumor of ovary | TxGNN Knowledge Graph |
| 10 | ovarian carcinosarcoma | TxGNN Knowledge Graph |
| 11 | primary non-gestational choriocarcinoma of ovary | TxGNN Knowledge Graph |
| 12 | ovarian cancer | TxGNN Knowledge Graph |
| 13 | malignant sex cord stromal tumor of ovary | TxGNN Knowledge Graph |
| 14 | immature ovarian teratoma | TxGNN Knowledge Graph |
| 15 | cervical carcinoma | TxGNN Knowledge Graph |
| 16 | maligant granulosa cell tumor of ovary | TxGNN Knowledge Graph |
| 17 | malignant dysgerminomatous germ cell tumor of ovary | TxGNN Knowledge Graph |
| 18 | small cell lung carcinoma | TxGNN Knowledge Graph |
| 19 | ovarian small cell carcinoma | TxGNN Knowledge Graph |
| 20 | malignant Sertoli-Leydig cell tumor of ovary | TxGNN Knowledge Graph |
| 21 | theca steroid-producing cell malignant tumor of ovary, not further specified | TxGNN Knowledge Graph |
| 22 | ovarian endometrioid adenocarcinoma | TxGNN Knowledge Graph |
| 23 | cervical carcinosarcoma | TxGNN Knowledge Graph |
| 24 | cervical cancer | TxGNN Knowledge Graph |
| 25 | ovarian mucinous adenocarcinoma | TxGNN Knowledge Graph |
Diese Vorhersagen dienen ausschließlich Forschungszwecken und stellen keine medizinische Beratung dar. Vor jeder klinischen Anwendung ist eine klinische Validierung erforderlich.